Orally administered vaccine can protect millions from hepatitis B. Oral vaccines are both safer and less expensive than injections. Therefore, researchers are continuously pursuing ways to produce an oral vaccine that is sufficiently effective. Now, University of Copenhagen physicists have delivered virologists a “recipe” for improving vaccine drops using methods from the world of nanophysics.
Millions of people are infected with hepatitis B every year. Hundreds of thousands die. And small children are particularly at risk. Due to high cost and the stable environmental conditions required for vaccine storage, many people in developing countries are not vaccinated against this dangerous virus. As such, researchers have been working to produce a drop or powdered form of oral vaccine. Oral vaccinations are cheaper and more easily administered than injections. However, developing a sufficiently effective oral hepatitis B vaccine has so far eluded researchers.
A joint collaboration from physicists at the Niels Bohr Institute, a team of researchers from University of São Paulo together with the Butantan Institute has introduced a technique to the pharmaceutical world that just might do the trick and lead to an optimal oral Hepatitis B vaccine.
“We have used a technology commonly used in solid state physics to explore how the vaccine behaves within a particular type of encapsulation. This has yielded crucial information that would not otherwise have been achievable. When we scientists venture beyond our comfort zone and deploy each other’s knowledge across disciplines, entirely new possibilities can emerge,” says Heloisa Bordallo, an associate professor at the Niels Bohr Institute, and one of the two main authors of the research article just published in Scientific Reports.
Three dimensional insight
A major challenge of making an oral vaccine is to encapsulate it in a material that can endure the harsh conditions of our digestive system, to protect the vaccine from being destroyed before it reaches its intended destination in the body. The Danish research team’s collaborative partners in Brazil have long known that the silica-material SBA-15 is well-suited to encapsulate a hepatitis B vaccine. However, they did not know exactly how the material protected the vaccine. Nor were they certain about why their vaccine was not always completely effective.
This is where the team of Danish physicists came into the picture. Using a special technique that combines x-ray and neutron imaging, researchers at the Niels Bohr Institute were able to produce 3D images of the inside of the SBA-15 silica. It marked a crucial step in the use of this technique to develop pharmaceuticals. The imagery allows researchers to see how the vaccine behaves inside the silica, right down to the particle scale. Among other things, they were able to see that the vaccine had a tendency to clump within the silica, making it less effective.
“Now we know what makes the vaccine less effective, and how to optimize it. We know exactly how much vaccine should be put in the silica capsule for it to work best in the body and the clinical trials can be better interpreted,” explains Heloisa Bordallo.
No more swelling and inflammation
The vaccine is particularly promising for developing nations, explains the other main author, Martin K. Rasmussen, a former student at the Niels Bohr Institute and current doctoral student at DTU:
“Getting rid of needles being poked into the arms of little children is an advantage in and of itself. It also eliminates any need to sterilize needles and possible side effects such as swelling and infection. And, unlike the vaccine in use today, this type of vaccine needn’t be refrigerated. As such, costs will be reduced and the vaccine’s administration will be eased.”
The researchers hope that the 3D technology will also be used to develop oral vaccines against several other types of disease. The goal of the Danish researchers’ Brazilian collaborative partners is to produce a 6-in-1 oral vaccine against diphtheria, tetanus, whooping cough, polio, Hib and hepatitis B. The vaccine against diphtheria and tetanus is already being developed.
Learn more: Needleless vaccine will protect children from dangerous viruses
The Latest on: Oral vaccines
via Google News
The Latest on: Oral vaccines
- Lyme disease prevention: Tarsus Pharmaceuticals initiates clinical trial for oral, non-vaccine TP-05on June 18, 2021 at 3:45 am
By NewsDesk @infectiousdiseasenews TP-05 is designed to kill infected ticks attached to the human body before they can transmit the Borrelia bacteria that causes Lyme disease Late clinical-stage ...
- Palace: Govt. may provide funding for oral COVID-19 vaccineon June 17, 2021 at 6:14 pm
Molecular biologist and OCTA Research fellow Fr. Nicanor Austriaco vows to make the vaccine as cheap as possible, as he intends its use for the poor.
- Oral Covid-19 vaccine delivery system being developed by UST scientist-prieston June 17, 2021 at 2:05 pm
Rev Fr Nicanor Austriaco, OP, PhD, head of the UST-Covax Vaccine Awareness Team, addressed the press in a briefing hosted by Malacañang today, where he advocated prioritizing the NCR+8 areas in order ...
- SARS-CoV-2 oral vaccine booster shows promise in animal testson June 15, 2021 at 5:35 pm
In a recent study published on the pre-print bioRxiv* server, a group of Israeli researchers discusses their progress towards developing an oral multi-antigen SARS-CoV-2 vaccine.
- NYC Health, Parks Departments Placing Oral Rabies Vaccines For Raccoons In Manhattan Parkson June 15, 2021 at 5:02 pm
New York City’s health and parks departments are teaming up to help protect raccoons from catching and spreading rabies. They are now placing bait that contains an oral rabies vaccine at Inwood Hill ...
- Why COVID Vaccine Stocks Dynavax, Novavax, and Vaxart Are Sinking Todayon June 15, 2021 at 12:50 pm
Shares of several COVID-19 vaccine makers were sinking on Tuesday morning. Dynavax Technologies ( NASDAQ:DVAX) stock was down 6.3% as of 11:26 a.m. EDT, while shares of Novavax ( NASDAQ:NVAX) and ...
- Israeli Covid-19 vaccine being developed as oral boosteron June 14, 2021 at 2:47 am
It turns out, however, that although the coronavirus vaccine market has become very competitive, the company has not abandoned the effort to develop the vaccine. In order to differentiate itself on ...
- Vaccines effective vs variants despite diminished antibodies; Oral booster vaccine shows promise in animal testson June 11, 2021 at 2:53 pm
The one-dose Johnson & Johnson COVID-19 vaccine and the two-dose vaccine from Pfizer and BioNTech appear to protect against worrisome coronavirus variants despite diminished levels of antibodies that ...
- Vaccines effective vs variants despite diminished antibodies; kids may be as contagious as adultson June 11, 2021 at 12:23 pm
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus. The one-dose ...
- Israeli oral COVID-19 vaccine en route to clinical trialson June 10, 2021 at 11:27 pm
Unlike the Pfizer or Moderna vaccines that use messenger RNA, this is an oral subunit vaccine, meaning the vaccine presents the antigen to the immune system without introducing pathogen particles.
via Bing News